B-cell childhood acute lymphoblastic leukemia

This phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…

This phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…

This phase 3 trial tests whether adding the targeted drug inotuzumab ozogamicin to standard chemotherapy and immunotherapy improves outcomes for children and young adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study will enroll about 6,000 participants an…

This study is testing a drug called inotuzumab ozogamicin, which is like a smart bomb that targets and kills leukemia cells, combined with low-intensity chemotherapy. The goal is to find the best dose and see if this combo works better than standard treatments for patients with a…

This study tests a combination of chemotherapy drugs (DA-EPOCH) plus an enzyme called asparaginase (Rylaze) in adults newly diagnosed with a fast-growing blood cancer (Philadelphia chromosome-negative ALL). The goal is to see if this mix can kill more cancer cells and achieve dee…

This phase II trial is testing whether adding two immunotherapy drugs (blinatumomab and inotuzumab ozogamicin) to a standard chemotherapy regimen (Hyper-CVAD) can improve outcomes for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The study plans to enro…

This phase 2 trial is testing a personalized cell therapy called CART19 in children and young adults with certain high-risk forms of B-cell acute lymphoblastic leukemia (B-ALL). The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack c…

This study tests a drug called tafasitamab in children aged 3 to 17 with B-cell leukemia that has come back or not responded to treatment. The drug is an antibody that helps the immune system find and kill leukemia cells. The trial has two parts: first, finding the best dose, and…

This early-phase study tests a new type of CAR T-cell therapy for adults with blood cancers like leukemia, lymphoma, and multiple myeloma that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack canc…

This study looks at whether giving blood transfusions only when hemoglobin drops below 7 gm/dL (instead of 9 gm/dL) is safe and maintains quality of life in leukemia patients after chemotherapy or stem cell transplant. About 50 adults with certain blood cancers will be randomly a…

This study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus,…

This study looks at why 20% of children with B-cell acute lymphoblastic leukemia (B-ALL) relapse after treatment. Researchers will collect bone and blood samples from 50 newly diagnosed children at three key points during therapy. They will study how a protein called CD9 is regul…